医学
安慰剂
内科学
随机对照试验
剂量范围研究
双盲
病理
替代医学
作者
Thomas Dörner,Simon Bowman,Robert I. Fox,Xavier Mariette,Athena Papas,Thomas Grader‐Beck,Benjamin A. Fisher,Filipe Barcelos,Salvatore De Vita,Hendrik Schulze‐Koops,Robert J. Moots,G. Junge,J. Woznicki,Monika Sopala,Alexandre Avraméas,Wen‐Lin Luo,Wolfgang Hueber
摘要
In patients with SjD, ianalumab 300 mg demonstrated sustained efficacy through week 52 and a favorable safety profile up to two years of follow-up.
科研通智能强力驱动
Strongly Powered by AbleSci AI